Navigation Links
Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obama's Announcement on Healthcare Reform
Date:6/25/2009

PRINCETON, N.J., June 25 /PRNewswire/ -- "Congratulations President Obama on your agreement with large pharmaceutical companies to cut prescription costs for the elderly," says Mark D. Steele, president of NeoStrata Company, Inc. "We thought you should know that you have a little company in New Jersey that's done the same for psoriasis sufferers of all ages."

Mr. Steele is speaking about NeoStrata Company, Inc., and the submission of their findings from a recent clinical study announcing the significant cost-savings associated with their non-prescription, psoriasis medicine PSORENT(R) psoriasis topical solution.

Earlier this week, NeoStrata Company, Inc. submitted results for publication from an 18 week long clinical study demonstrating how psoriasis patients can save hundreds of dollars a year with their novel, non-prescription psoriasis therapy that has outperformed the leading non-steroidal prescription topical in treating the redness and scaling of psoriasis.

"In these economic times we are thrilled to be able to offer a psoriasis medicine that does not require a prescription, is significantly less expensive than most prescription drugs for psoriasis, and performs as well or better than a leading prescription medication," says Mr. Steele.

"This is not a story you hear very often, and as a small company," he explains, "we are just very excited and proud of this new psoriasis therapy and of the value it presents to patients."

NeoStrata Company, Inc. has spent the last few years developing PSORENT(R) and conducting clinical studies and after just receiving the cost savings analyses agrees the timing couldn't be better in tune with what's happening in the economy.

"As a small company," Steele explains, "we have created an affordable and preferable treatment for psoriasis that can save patients hundreds and thousands of dollars in healthcare costs, and we want you to know that we are with you, Mr. President."

About PSORENT(R)

PSORENT(R) is a new topical solution that has the proven efficacy of a prescription medication but is available as an OTC. This aesthetically advanced, quick-drying solution is highly effective, easy and pleasant to use, and has a patient satisfaction rating of nearly 90%.

About NeoStrata

NeoStrata Company, Inc., located in Princeton, NJ develops and markets a comprehensive range of clinically-proven, dermatologist developed skin care products. These advanced therapeutic and cosmetic dermatological products are available worldwide through consumer outlets, physicians' offices and spas.

More information is available at www.neostrata.com and www.psorent.com.


'/>"/>
SOURCE NeoStrata Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
4. Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
7. Innovative Brain Scanning for Alzheimers Screening Unveiled
8. Gates Foundation Seeks Proposals for Innovative Global Health Research
9. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
10. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
11. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year since ... $394.9 billion. The consequences of rapid innovation and growth are often neglected in ... it is every business and individual’s job to give something back to the planet ...
(Date:4/22/2017)... ... April 22, 2017 , ... The San Juan Capistrano summer camp team ... report outlining the need for summer camps to provide physical activities for all campers. To ... Activity In Summer Camps , With an increase in specialty camps that focus on what ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 and ... of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset ... services to communities throughout the greater Pittsburgh metropolitan region, is joining forces with ... adaptive bicycles for differently-abled children. , Variety the Children’s Charity is a national ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA Agency , ... for Theravent, Inc. , the makers of a revolutionary new device clinically ... is now working to expand distribution in anticipation of a national launch. VIA ...
Breaking Medicine News(10 mins):